CASE REPORT

Pneumothorax triggered by EGFR-tyrosine kinase inhibitors in three microwave ablation candidates: A review of the literature

Runqi Guo1,2, Yuanming Li1,2, Zhixin Bie1,2, Bin Li1,2 & Xiaoguang Li1,2

1 Minimally Invasive Tumor Therapies Center, Beijing Hospital, National Center of Gerontology, Beijing, China
2 Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China

Keywords
Microwave ablation; non-small-cell lung cancer; pneumothorax; tyrosin kinase inhibitor.

Abstract
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are widely used in patients with EGFR-mutant lung cancer. Meanwhile, thermal ablation such as microwave ablation has been an option for selected patients. Herein, we describe three cases of pneumothorax that occurred in microwave ablation (MWA) candidates treated with EGFR-TKIs. The three patients developed pneumothorax in different periods: case 1 developed pneumothorax two months after MWA and subsequent gefitinib therapy; case 2 took osimertinib for two years and developed pneumothorax before MWA; case 3 took gefitinib for 13 months and experienced bronchopleural fistula after MWA. Although a causal relationship is uncertain, the risk of pneumothorax for these MWA candidates should be considered.

Key points:
• Microwave ablation candidates treated with epidermal growth factor receptor tyrosine kinase inhibitors are more likely to suffer pneumothorax.
• The risk of delayed pneumothorax or even bronchopleural fistula in patients pretreated with tyrosine kinase inhibitors should be taken into consideration when selecting patients and performing microwave ablations.

Introduction
In recent years, image-guided percutaneous thermal ablation techniques including radiofrequency ablation, microwave ablation (MWA), and cryoablation, have evolved as minimally invasive treatment options for selected patients with inoperable lung cancer or those resistant to systemic therapy.1–4 Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are widely used in patients with EGFR mutation. In this study, we reviewed three cases of pneumothorax that occurred in MWA candidates treated with EGFR-TKIs.

Case report

Case 1
A 60-year-old male ex-smoker presented with an incidental left lower lobe round pulmonary nodule (3.2 × 3.0 cm) (Fig 1a). A computed tomography (CT)-guided biopsy confirmed EGFR-mutant adenocarcinoma of the lung. The patient refused pulmonary resection and then received percutaneous MWA (Fig 1b,c). He subsequently received gefitinib. Two months after MWA, he complained of a brutal chest pain and noticed a swelling of his chest. A chest CT scan identified a 70% left-sided pneumothorax (Fig 1d). An eight French loop catheter was placed. The left lung re-expanded fully under low-negative pressure within 24 hours and remained fully expanded after two weeks (Fig 1e). Gefitinib was continued throughout. Follow-up chest CT at 10 months after MWA showed a shrinking fibrotic scar (Fig 1f).

Case 2
A 69-year-old female non-smoker presented with cough and shortness of breath. A chest CT showed a right lung primary tumor and mediastinal lymph node metastasis.
She refused biopsy or surgery. She was clinically diagnosed with lung cancer and received icotinib. After nine months, she was commenced on osimertinib due to disease progression. Her two-year assessment showed the lesion had grown (Fig 2a). On the day of the procedure, a chest CT scan demonstrated a 80% right-sided pneumothorax (Fig 2b). Continuous catheter (12 French) drainage under low-negative pressure was utilized. Four days later, the pneumothorax was relieved and a simultaneous CT-guided biopsy and MWA of the right lower lobe pulmonary nodule (2.5 × 2.0 cm) was performed (Fig 2c,d). The pathology confirmed that it was adenocarcinoma of the lung. She received bronchial arterial chemoembolization after two months.

Case 3

A 65-year-old male ex-smoker presented with complaints of facial numbness. A CT scan revealed a left pulmonary mass and two ground-glass opacities (GGOs) in the right lung. Subsequent biopsy confirmed EGFR-mutant adenocarcinoma of the lung. He was started on gefitinib treatment. Regular CT scans demonstrated that the two GGOs had disappeared and that the left pulmonary lesion had shrunk and then grown after approximately 13 months (Fig 3a). The patient received simultaneous CT-guided repeat biopsy and MWA of the left pulmonary lesion (4.2 × 3.2 cm) (Fig 3b,c). The pathology confirmed that it was sarcomatoid carcinoma. After two weeks, dyspnea with fever was noted. The chest CT confirmed left pneumothorax and pleural effusion (Fig 3d). Two 10 French loop catheters were placed. CT scan showed bronchopleural fistula after 10 days (Fig 3e). Thus, one catheter was connected with water sealed bottle, and another was removed. The catheter was removed after a clamp test one month later (Fig 3f).

Discussion

Pneumothorax is the most common complication after ablation, with an incidence of 10%–67%, while pneumothorax as a result of response to anticancer therapy is rare in oncology and typically occurs in cases of metastatic carcinoma, especially in cases of sarcoma.

Although pneumothorax has been described in primary...
lung cancer on initial presentation or as a complication, they are very rarely associated with cytotoxic chemotherapy.\(^7\) Tumor necrosis, check valve with compression of airway, tumor embolus, cavitary and pleural-based lung lesion, may contribute to the development of pneumothorax.\(^8\) It has been suggested that cytotoxic agents and angiogenesis inhibitors may induce tumor necrosis and cavitations in lung lesions, which may be signs of clinical response but also be risk factors of rupture into the pleural cavity and the development of bronchopleural fistula during chemotherapeutic agents or EGFR-TKI treatment.\(^9\) Pneumothorax during bevacizumab treatment, another angiogenesis inhibitor, is a frequent occurrence.\(^10\) Moreover, pneumothorax during pazopanib, erlotinib, or crizotinib has also been reported,\(^11\) with a rate of 14% among patients treated with pazopanib,\(^12\) and 1% for advanced non-small cell lung cancer (NSCLC) patients treated with erlotinib.\(^13\)

In our observation, the three patients had subpleural lung cancers. According to a recent study on thermal ablation for subpleural lung cancers, the rate of pneumothorax was approximately 5%, and the tumor adjacent to pleura did not increase the risk.\(^14\) However, EGFR-TKI could affect the growth and repair of epithelial cells, which may be one of the incentives. In addition, the timing or duration of EGFR-TKI therapies did not matter the results. Some patients may experience disease progression slowly during EGFR-TKI treatment and show disease-free survival benefits.\(^15\) Local treatment might be an alternative option for selected patients who cannot tolerate the side-effects, afford new generation TKIs, or are resistant to current therapies. In our institution, intratumoral injection of hypertonic glucose is utilized to prevent post-procedure pneumothorax for high risk patients with neoadjuvant EGFR-TKI treatment. Hypertonic glucose can induce pleural aseptic inflammation and make two layers of pleura adhere together.\(^16\)

In conclusion, here we report three cases of pneumothorax that occurred during EGFR-TKI treatment in MWA candidates with NSCLC. Although a causal relationship is uncertain, it is possible that the pneumothorax occurred due to EGFR-TKI treatment with/without

---

**Figure 2** Case 2, a 69-year old female patient. (a) CT scan showed that the right lung primary tumor and mediastinal lymph node metastasis had enlarged at the two-year assessment following osimertinib therapy. (b) A pneumothorax developed before MWA. (c) The pneumothorax was relieved after drainage, no cavitation or tumor progression was observed, and biopsy simultaneous with MWA was performed. (d) Catheter drainage was removed.
MWA. Notably, according to our experience, the risk of pneumothorax, or even bronchopleural fistula may be higher in patients pretreated with EGFR-TKIs and this should be taken into consideration when selecting patients and performing MWA.

Acknowledgments

Not applicable.

Disclosure

The authors report that there are no conflicts of interest.

References

1. NCCN. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) Non-Small Cell Lung Cancer. Version 1.2020 2019 Available from URL: https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf.
2. Dupuy DE. Image-guided thermal ablation of lung malignancies. Radiology 2011; 260 (3): 633–55.
3. Pereira PL, Masala S. Cardiovascular and Interventional Radiological Society of Europe (CIRSE). Standards of practice: Guidelines for thermal ablation of primary and secondary lung tumors. Cardiovasc Intervent Radiol 2012; 35 (2): 247–54.
4. Ye X, Fan W, Wang H et al. Expert consensus workshop report: Guidelines for thermal ablation of primary and
metastatic lung tumors (2018 edition). J Cancer Res Ther 2018; 14 (4): 730–44.
5 Nakahara Y, Fukui T, Katono K et al. Pneumothorax during Pazopanib treatment in patients with soft-tissue sarcoma: Two case reports and a review of the literature. Case Rep Oncol 2017; 10 (1): 333–8.
6 Sabath B, Muhammad HA, Balagani A et al. Secondary spontaneous pneumothorax in patients with sarcoma treated with Pazopanib, a case control study. BMC Cancer 2018; 18 (1): 937.
7 Lai RS, Perng RP, Chang SC. Primary lung cancer complicated with pneumothorax. Jpn J Clin Oncol 1992; 22 (3): 194–7.
8 Lee MJ, Kim EK, Kim MJ, Kwak JY, Hong S, Park CS. Spontaneous pneumothorax in metastatic thyroid papillary carcinoma. J Clin Oncol 2007; 25 (18): 2616–8.
9 Interiano RB, McCarville MB, Wu J, Davidoff AM, Sandoval J, Navid F. Pneumothorax as a complication of combination antiangiogenic therapy in children and young adults with refractory/recurrent solid tumors. J Pediatr Surg 2015; 50 (9): 1484–9.
10 Zhang Y, Yang H, Zhao M, He J. Bilateral pneumothorax after bevacizumab-containing chemotherapy in fibrosarcoma. J Thorac Dis 2012; 4 (2): 229–31.
11 Gennatas S, Stanway SJ, Thomas R et al. Early pneumothorax as a feature of response to crizotinib therapy in a patient with ALK rearranged lung adenocarcinoma. BMC Cancer 2013; 13: 207.
12 Verschoor AJ, Gelderblom H. Pneumothorax as adverse event in patients with lung metastases of soft tissue sarcoma treated with pazopanib: A single reference Centre case series. Clin Sarcoma Res 2014; 4: 14.
13 Nakagawa K, Garon EB, Seto T et al. Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2019; 20 (12): 1655–69.
14 Cao F, Xie L, Qi H et al. Safety and efficacy of thermal ablation for subpleural lung cancers. Thorac Cancer 2019; 10 (6): 1340–7.
15 Liu X, Wang P, Zhang C, Ma Z. Epidermal growth factor receptor (EGFR): A rising star in the era of precision medicine of lung cancer. Oncotarget 2017; 8 (30): 50209–20.
16 Tsukioka T, Inoue K, Oka H, Mizuguchi S, Morita R, Nishiyama N. Intraoperative mechanical and chemical pleurodesis with 50% glucose solution for secondary spontaneous pneumothorax in patients with pulmonary emphysema. Surg Today 2013; 43 (8): 889–93.